Sir -Numerous studies have revealed that the immunological effects of treatment with recombinant interleukin 2 (rIL-2) are dose and schedule dependent. Continuous and prolonged treatment with rIL-2 leads to a sustained increase in the number of natural killer (NK) cells and enhanced NK activity (Caligiuri et al., 1993; Vlasveld et al., 1993) . Janssen et al. and others have shown that T-cell activation and expansion also occur within the first weeks of treatment and appear to be transient (Thompson et al., 1989; Yoshino et al., 1991; Janssen et al., 1993) . It is likely that we missed the signs of T-cell activation because of the timing of the immunological analysis in our study (Vlasveld et al., 1993) .
In our recent study of continuous infusion of low-dose rIL-2 and a monoclonal antibody directed against the B-cellspecific antigen CD.19, we found signs of T-cell activation (enhanced expression of CD25 and HLA-DR on CD3+ cells) after 1 week of treatment and a transient increase in circulating T cells during the first weeks of treatment in the majority of patients (Vlasveld et al., unpublished data) . The proposed T-cell anergy occurring during prolonged rIL-2 treatment is in accord with experimental data that T cells (especially CD4+) may become refractory to continued in vitro exposure to IL-2 and revert to the resting stage (Cantrell et al., 1983; Gulberg & Smith, 1986) .
Although the role of cytotoxic T-cells in eradicating tumours has been established in several animal models, in man the anti-tumour effect of rIL-2-induced T-cell activation has not been demonstrated. The limited anti-tumour effect that we noted in our patients occurred during the first weeks of treatment, however it was not related to the observed signs of activation of circulating T-cells (Vlasveld et al., 1992, 1993 and unpublished data 
